How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/complicated-skin-and-skin-structure-infection.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Complicated Skin and Skin Structure Infection — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Complicated Skin and Skin Structure Infection (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Complicated Skin and Skin Structure Infection, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Vibativ	TELAVANCIN	Cumberland	Lipoglycopeptide Antibacterial		2009-01-01
Vibativ	TELAVANCIN HYDROCHLORIDE	Cumberland	Lipoglycopeptide Antibacterial		2009-01-01
Tygacil	TIGECYCLINE	Fresenius Kabi	Tetracycline-class Antibacterial [EPC]	30S ribosomal subunit	2005-01-01
Invanz	ERTAPENEM	Merck & Co.	Penem Antibacterial		2001-01-01
Avelox	moxifloxacin	Bayer AG	Fluoroquinolone antibiotic (fourth-generation)	DNA gyrase, DNA gyrase subunit A, DNA topoisomerase 4 subunit A	1999-12-10
Levaquin	levofloxacin	Generic (originally Daiichi Sankyo/J&J)	Fluoroquinolone Antibacterial [EPC]	CAAX prenyl protease 2, Multidrug and toxin extrusion protein 1, Potassium voltage-gated channel subfamily H member 2	1996-12-20
Merrem	Meropenem	Pfizer	meropenem		1996-01-01
Zosyn	TAZOBACTAM	Merck Sharp & Dohme B.V.	beta Lactamase Inhibitor		1993-01-01
Merrem	Merrem	National Institutes of Health Clinical Center (CC)		Beta-lactamase, Beta-lactamase NDM-1, Beta-lactamase class B VIM-2
Avelox	Avelox	Novartis Pharmaceuticals		DNA gyrase, DNA gyrase subunit A, DNA topoisomerase 4 subunit A

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 3 drugs in Complicated Skin and Skin Structure Infection
Pfizer · 2 drugs in Complicated Skin and Skin Structure Infection
Cumberland · 2 drugs in Complicated Skin and Skin Structure Infection
Assistance Publique - Hôpitaux de Paris · 1 drug in Complicated Skin and Skin Structure Infection
Fresenius Kabi · 1 drug in Complicated Skin and Skin Structure Infection
Generic (originally Daiichi Sankyo/J&J) · 1 drug in Complicated Skin and Skin Structure Infection
Merck & Co. · 1 drug in Complicated Skin and Skin Structure Infection
Merck Sharp & Dohme B.V. · 1 drug in Complicated Skin and Skin Structure Infection
National Institutes of Health Clinical Center (CC) · 1 drug in Complicated Skin and Skin Structure Infection
Novartis Pharmaceuticals · 1 drug in Complicated Skin and Skin Structure Infection
Bayer AG · 1 drug in Complicated Skin and Skin Structure Infection

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Complicated Skin and Skin Structure Infection:

Cite this brief

Drug Landscape (2026). Complicated Skin and Skin Structure Infection — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/complicated-skin-and-skin-structure-infection. Accessed 2026-06-10.

Complicated Skin and Skin Structure Infection full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing